Coherus Oncology refinances with $55M term loan, pushes debt maturity to 2031

What's the deal? Coherus Oncology (NASDAQ: CHRS) secured a $55 million senior secured term loan with Innovatus Capital PartnersDealroom has a profile for this one. Try Dealroom →' affiliated life-sciences lending platform. The loan agreement was signed on 12 August 2026, and the full Tranche A amount was drawn on 14 August.

Why now? The refinancing extends Coherus's debt maturity from May 2029 to August 2031, reducing near-term refinancing pressure ahead of key product launches.

What's the endgame? The facility repays existing debt and supports working capital and general corporate purposes. Coherus can draw an additional $25 million and $20 million under certain conditions.

The loan carries a floating rate of 4.15% plus the greater of Prime Rate or 6.75%, includes a 36-month interest-only period, and is secured by substantially all of the company's assets, including intellectual property.

The signal: The refinancing gives Coherus more time to reach commercial milestones before its debt comes due.

Read more: MiniChart · SEC filing

Image credit: Generated with Gemini